Urinary thrombin as a marker of local disseminated intravascular coagulation in patients with chronic kidney disease

I.S. Mykhaloiko

doi:10.26641/2307-0404.2021.4.248157

Authors

I.S. Mykhaloiko Ivano-Frankivsk National Medical University Halytska str., 2, Ivano-Frankivsk, 76000, Ukraine https://orcid.org/0000-0002-7943-9029

DOI:

https://doi.org/10.26641/2307-0404.2021.4.248157

Keywords:

disseminated intravascular coagulation syndrome, chronic kidney disease, glomerulonephritis, diabetic nephropathy, thrombin

Abstract

The aim of this research was to study the diagnostic markers of nonovert local disseminated intravascular coagulation (DIC) syndrome in the urine of patients with chronic kidney disease (CKD). We conducted a prospective study involving 140 patients with CKD, of these patients, 100 patients (71.4%; 95% CI 53.4-76.7) had glomerulonephritis (GN) and 40 patients (28.6%; 95% CI 21.3-36.8) had diabetic nephropathy (DN). We diagnosed overt DIC syndrome on the International Society of Thrombosis and Haemostasis (ISTH) scale (>5 points) in 18.6 % of patients. We determined the level of thrombin in the urine of patients who had <5 points on ISTH scale for the diagnosis of local nonovert DIC syndrome in the kidneys. In the urine of healthy individuals, the level of thrombin did not exceed 1 ng/ml, so we found no thrombinuria at a thrombin level <1 ng/ml. In 56.1% of patients, we found urinary thrombin levels >1 ng/ml. The average level of thrombin in the urine of these patients was 6.5 (4.8; 10.6) ng/ml. In our opinion, the presence of thrombinuria indicates the intensity of monocytic-macrophage inflammation in the glomeruli and may be a criterion for nonovert, local DIC syndrome in the kidneys. The association of overt DIC syndrome with decreased blood albumin, reduced glomerular filtration rate (GFR), increased daily protein excretion (DPE) indicates its occurrence in severe underlying disease, in the presence of nephrotic syndrome and in the severe stages of CKD. Early diagnosis of nonovert local DIC syndrome would be more useful, since the process is still reversible and controlled, and timely use of antiplatelet and anticoagulant therapy would affect the course and the progression of CKD.

References

Fetisov VS. [STATISTICA statistical data ana¬lysis package]. Nizhyn: NDU im. M. Gogolya; 2018. p. 114. Ukrainian.

Aursulesei V, Costache I. Anticoagulation in chronic kidney disease: from guidelines to clinical prac¬tice. Clin Cardiol. 2019;42:774-782. doi: https://doi.org/10.1002/clc.23196

Falay M, Senes M, Korkmaz S, Turhan T, Okay M, Ozturk BA, Yucel D, Ozet G. Biological va¬riation estimates of prothrombin time, activated partial thromboplastin time, and fibrinogen in 28 healthy individuals. Int J Lab Hematol. 2018;40(6):721-25. doi: https://doi.org/10.1111/ijlh.12910

Kaido T, Yoda M, Kamijo T, Taira C, Higuchi Y, Okumura N. Comparison of molecular structure and fibrin polymerization between two Bbeta-chain N-terminal region fibrinogen variants, Bbetap.G45C and Bbetap.R74C. Int J Hematol. 2020;112(3):331-40. doi: https://doi.org/10.1007/s12185-020-02919-5

Papageorgiou Ch, Jourdi G, Adjambri E, Walborn A, Patel P, Fareed J, Elalamy I, Hoppensteadt D, Gero¬tziafas G. Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies. Clinical and Applied Thrombosis/Hemostasis. 2018;24:8-28. doi: https://doi.org/10.1177/1076029618806424

Kanno H, Kanda E, Sato A, Sakamoto K, Kanno Y. Estimation of daily protein intake based on spot urine urea nitrogen concentration in chronic kidney di¬sease patients. Clin Exp Nephrol. 2016;20(2):258-64. doi: https://doi.org/10.1007/s10157-015-1164-5

Kitamoto Y, Tomita K, Imamura T. Assessment of thrombin in the urine of glomerulonephritic patients by enzyme-linked immunosorbent assay. Ann Clin Biochem. 2004;41:133-7. doi: https://doi.org/10.1258/000456304322880023

Kolesnyk M. Innovative directions of CKD prevention and treatment. Ukr J Nephr Dial. 2019;1(61):3-12. doi: https://doi.org/10.31450/ukrjnd.1(61).2019.01

Kolesnyk M, Liksunova L, Selezneva T, et al. The cost of dialysis renal replacement therapy for end-stage renal disease patients in Ukraine. Ukr J Nephr Dial. 2019;4(64):4-10. doi: https://doi.org/10.31450/ukrjnd.4(64).2019.01

Chen HJ, Chen RLC, Hsieh BC, Hsiao HY, Kung Y, Hou YT, Cheng TJ. Label-free and reagentless capacitive aptasensor for thrombin. Biosens Bioelectron. 2019 Apr 15;131:53-59. doi: https://doi.org/10.1016/j.bios.2019.02.025

Levi M, Sivapalaratnam S. Disseminated intravascular coagulation: an update on pathogenesis and diag¬nosis. Expert Rev Hematol. 2018;11(8):663-72. doi: https://doi.org/10.1080/17474086.2018.1500173

Meelu OA. Platelet Counts: A Word of Wisdom. Am J Cardiol. 2017;120(3):17. doi: https://doi.org/10.1016/j.amjcard.2016.05.034

Mora S, Goicoechea M, Torres E. Cardiovascular risk prediction in chronic kidney disease patients. Nefrologia. 2017;37(3):293-300. doi: https://doi.org/10.1016/j.nefro.2016.10.002

Tripodi A. Thrombin Generation Assay and Its Application in the Clinical Laboratory. Clin Chem. 2016;62(5):699-707. doi: https://doi.org/10.1373/clinchem.2015.248625

Kitamoto Y, Arizono K, Fukui H, et al. Urinary thrombin: a novel marker of glomerular inflammation for the diagnosis of crescentic glomerulonephritis (prospective observational study). PLoS One. 2015;10(3):e0118704. doi: https://doi.org/10.1371/journal.pone.0118704

Weitz JI, Fredenburgh JC, Eikelboom JW. A Test in Context: D-Dimer. J Am Coll Cardiol. 2017;70(19):2411-20. doi: https://doi.org/10.1016/j.jacc.2017.09.024

Xiao J, Melvin RL, Salsbury FR. Mechanistic insights into thrombin's switch between "slow" and "fast" forms. Phys Chem Chem Phys. 2017 Sep 20;19(36):24522-33. doi: https://doi.org/10.1039/C7CP03671J